Fundraising FoxQiming Healthcare — Full Portfolio
10 tracked investments · listed companies and verified rows first
Boulder provides medication-assisted treatment for addiction through licensed specialists who prescribe buprenorphine, supported by dedicated care teams offering medical care, peer recovery coaching, and care coordination accessible via a digital platform.
Digital HealthHealthtechMental HealthBoulder, US
Stephanie Papes(Cofounder)Stephanie Strong(Founder)Jordan Nof(Director)Frank Ingari(Director)Josh Kopelman(Director)
Board seatMark McDade· per SEC Form D · $41.6M raise · filed May 2022
Co-investorsAdvance Venture PartnersAlumni VenturesFirst Round CapitalGaingelsGreycroftLaerdal Million Lives Fund+5 more
__Twitter.png)
HealthtechMenlo Park, US
Thomas G. Wiggans(Executive Officer, Director)inEugene A. Bauer(Executive Officer, Director)Andrew Guggenhime(Executive Officer)Luis Pena(Executive Officer)Christopher Griffith(Executive Officer)
BoardFred Craves(Director)in
Board seatMark D. McDadeMark McDade· per SEC Form D · $1M raise · filed Dec 2018
Co-investorsAisling CapitalBay City CapitalCanaan PartnersForesite CapitalNew Enterprise Associates (NEA)Fidelity Investments+1 more
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Greg Lazar, Ph.D.(Co-Founder and Chief Scientific Officer)Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in
BoardAlicia Levey(Director)
Board seatMark McDade· per SEC Form D · $66.6M raise · filed Nov 2025
Co-investorsQiming Venture PartnersSV Health InvestorsVersant VenturesAlexandriaDementia Discovery FundQiming Venture Partners USA
Vaccine development platform using computationally designed synthetic virus-like particles
BiotechSeattle, US
Charles Richardson(Senior Vice President, Technical Operations)Adam K. Simpson(President and Chief Executive Officer)Niranjan Kanesa-thasan(Chief Medical Officer)Douglas A. Holtzman(Chief Scientific Officer and Secretary)Cassia Cearley(Treasurer, Chief Business Officer)
BoardPeter Kolchinsky(Director)in
Board seatMark McDade· per SEC Form D · $51M raise · filed Oct 2019
Co-investorsQiming Venture Partners USARA CapitalSanofi VenturesViking GlobalQiming Venture Partners
BiotechChestnut Hill, US
Joseph Italiano(Director)inJonathan Thon(Director)Sven Erik Karlsson(Executive Officer)Peter Finn(Executive Officer)
Board seatMark McDade· per SEC Form D
Co-investorsBoston Harbor AngelsThird Rock VenturesVivo Capital
Clinical-stage biotech developing cell therapy products for transplant and autoimmune conditions
BiotechLouisville, US
Suzanne Ildstad(Executive Officer, Director)Scott Requadt(Executive Officer, Director)Geoff Mackay(Director)Francois Nader(Director)
BoardSandip Agarwala(Director)in
Board seatMark McDade· per SEC Form D · $115M raise · filed Oct 2020
Co-investorsAisling CapitalKeyhorse CapitalLongitude CapitalQiming Venture Partners USAViking GlobalBlackstone Life Sciences+3 more
WindMIL Therapeutics is a clinical-stage biotechnology company developing cell-based immuno-oncology therapies using marrow-infiltrating lymphocytes (MILs), T cells extracted from a cancer patient's bone marrow that are activated and expanded before being returned to the patient.
BiotechMedical DevicesPrinceton, US
Ivan Borrello(Founder)Kimberly Noonan(Founder)in
BoardBrian Halak(Executive Officer, Director)
Board seatAnna FrenchMark McDade· per SEC Form D · $5M raise · filed Feb 2021
Co-investorsQiming Venture Partners USA
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.